Introduction {#Sec1}
============

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and leading to peripheral cytopenias and a genetic instability with enhanced risk of disease transformation to acute myeloid leukemia (AML).

In the general population, MDS affects approximately five in every 100,000 individuals and is regarded as a relatively rare disease \[[@CR1]\]. However, its incidence is highest in people aged \>70 years, and in this age group, MDS is the most frequently occurring malignant hematological disorder: twice as frequent as AML, more common than chronic lymphocytic leukemia, and more common than all other malignant lymphomas combined \[[@CR2]\]. All patients diagnosed with MDS will eventually die from their disease, and in about 30%, the disease will progress to AML \[[@CR3]\].

Between 40% and 60% of patients with primary MDS and about 90% of patients with secondary MDS have chromosomal abnormalities at the time of diagnosis \[[@CR4]\]. Chromosomal abnormalities may occur as a single abnormality or as part of a complex karyotype; disease severity increases with the number of abnormalities. The most common chromosomal abnormalities are deletions of chromosome 5 and chromosome 7 and trisomy of chromosome 8 \[[@CR5]\]. In a subgroup of patients who have an isolated deletion 5q (del(5q)), termed 5q-syndrome, the clinical profile is distinct \[[@CR6]\]. Typically, this clinical profile includes macrocytic anemia, a normal to increased platelet count, mild leukopenia, hypolobulated megakaryocytes in the bone marrow, a medullary blast count \<5%, and an isolated del(5q) abnormality including a common deleted region between 5q31 and 5q33 \[[@CR4], [@CR7]\]. Consistent with the observation that disease severity is related to the number of chromosomal abnormalities, patients with del(5q) plus additional cytogenetic abnormalities have a worse prognosis than those with an isolated del(5q) abnormality \[[@CR3], [@CR5]\].

On the basis of the results of an international phase II trial in 148 patients \[[@CR8]\], the oral immunomodulatory, antiangiogenic, and antineoplastic agent lenalidomide (Revlimid®; Celgene Corporation, NJ, USA) was approved in December 2005 by the US Food and Drug Administration (FDA) for the treatment of patients with transfusion-dependent International Prognostic Scoring System (IPSS) classified low-risk to intermediate-1-risk MDS with a del(5q) cytogenetic abnormality, with or without additional cytogenetic abnormalities. The first 46 patients recruited received lenalidomide 10mg/day for 21days every 28-day cycle, for up to 24weeks. After a protocol amendment, the remaining 102 patients received lenalidomide 10mg/day on a continuous dosing schedule \[[@CR8]\]. Overall, 67% of patients who were initially transfusion-dependent achieved transfusion independence, and another 9% achieved a decrease (≥50%) in the total number of transfusions required during lenalidomide therapy \[[@CR8]\]. Forty-five percent of the 85 evaluable patients in this study achieved a complete cytogenetic response, irrespective of chromosomal complexity \[[@CR8]\].

In January 2007, an international group of MDS specialists met to discuss the practical management of lenalidomide in patients with transfusion-dependent, IPSS-classified low-risk or intermediate-1-risk MDS and a del(5q) cytogenetic abnormality. The recommendations presented here are based on the clinical data derived from the current literature \[[@CR8], [@CR9]\], from the known clinical profile of lenalidomide in other disorders, and the clinical experience of the panel members in the practical use of this agent. Although lenalidomide has been used in IPSS-classified intermediate-2-risk and high-risk patients and in patients without an associated del(5q) abnormality, the recommendations presented here focus on the current approved indication of the drug in the USA.

Selection of patients for lenalidomide therapy {#Sec2}
==============================================

The FDA approved lenalidomide for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a del(5q) cytogenetic abnormality, with or without additional cytogenetic abnormalities. This is an important limitation, as patients with a complex karyotype and del(5q) are eligible for treatment *only* if they have no more than one cytopenia (i.e., anemia, neutropenia, or thrombocytopenia) and their medullary bone marrow blast count is \<5%. Furthermore, patients with a bone marrow blast count up to 10% receive a score of 0.5 points in the IPSS classification (Table [1](#Tab1){ref-type="table"}) \[[@CR3]\]. Therefore, in order to remain in the IPSS intermediate-1-risk category, one additional chromosomal abnormality (not involving chromosome 7) or two or more peripheral cytopenias are allowed, but not both. Although teratogenicity has not been reported with lenalidomide, as it is an analogue of thalidomide, women of childbearing potential should have two negative pregnancy tests performed within 14days prior to lenalidomide intake. Table 1International prognostic scoring system for myelodysplastic syndromes: survival and evolution of acute myeloid leukemia Score valuePrognostic variable00.51.01.52.0Bone marrow blasts, %\<55--10--11--2021--30Karyotype^a^GoodIntermediatePoor  Cytopenias^b^0/12/3   Scores for risk groups are as follows: Low, 0; Int-1, 0.5--1.0; Int-2, 1.5--2.0; and High, ≥2.5^a^Good: normal, −Y, isolated del(5q), isolated del(20q); poor: ≥3 abnormalities or chromosome 7 anomalies; intermediate: other abnormalities^b^Neutrophils \<1800 × 10^6^/l, hemoglobin \<10 g/dl, platelets \<100 × 10^9^/lTable reproduced with permission from \[[@CR3]\] © The American Society of Hematology

Lenalidomide therapy is effective regardless of prior erythropoietin \[[@CR8], [@CR9]\] or prior thalidomide therapy \[[@CR9]\], and those previous therapies should not be regarded as contraindications for its use, although concurrent therapy with erythropoietin is not recommended, owing to concerns regarding venous thromboembolism.

Clinical data have shown that the frequency of response to lenalidomide is similar across all age groups evaluated \[[@CR8]\]. Importantly, the overall adverse-event burden did not increase in older patients, but serious adverse events were more frequent in patients aged over 65years compared with younger patients (54% vs. 33%, respectively) \[[@CR10]\].

Although the impact of renal impairment on lenalidomide efficacy or toxicity in patients with MDS has not been evaluated, the risk of toxicity is expected to be greater in patients with impaired renal function because lenalidomide is renally excreted \[[@CR11]\]. In patients with known renal impairment, the expert panel support the dosing schedule proposed by Chen et al., which is based on creatinine clearance (Table [2](#Tab2){ref-type="table"}) \[[@CR11]\]. As advancing age is associated with declining renal function, it is recommended that patients older than 65years who are prescribed lenalidomide are monitored carefully throughout their treatment (Table [3](#Tab3){ref-type="table"}). Table 2Recommended dose adjustments for patients with impaired renal function^a^Renal impairmentDoseMild10 mg (full dose) every 24 h (80 \> CL~cr~ ≥ 50 ml/min)Moderate5 mg every 24 h (30 ≤ CL~cr~ \< 50 ml/min)Severe5 mg every 48 h (CL~cr~ \< 30 ml/min, not requiring dialysis)End-stage renal disease5 mg three times a week after each dialysis (CL~cr~ \< 30 ml/min, requiring dialysis)^a^Recommendations based on a pharmacokinetic study by Chen et al. \[[@CR11]\]*CL*~*cr*~ creatinine clearanceTable adapted from \[[@CR11]\] © 2007 SAGE Publications. Adapted by permission of SAGE Publications, Inc.Table 3Recommendations for laboratory monitoring during treatmentFunctionTestRecommendation(s)Kidney functionCreatinineEvery 4 weeks in patients aged 65 years and olderBloodFBCWeekly monitoring of full blood count mandatory for the first 2 months (it may be continued for 5 months).Biweekly or monthly monitoring should be considered thereafter, depending on hematological status.If treatment is interrupted in patients who had a previous episode of neutropenia or thrombocytopenia while on lenalidomide treatment, the same monitoring guidelines apply at re-initiationThyroid functionTSH, T~4~Monitor every month during the course of treatmentIn case of loss of response during lenalidomide treatmentGonadal functionTestosteroneIn case of loss of response during lenalidomide treatmentDigoxinDigoxinIn patients concomitantly taking Digoxin, the plasma level should be monitored periodicallyPregnancy testUrine testDay −14 and day 0 at initiation of therapy, monthly thereafter (in women of childbearing potential)Bone marrowBM aspiration and cytogenetic testing; Trephine biopsy optionalAt commencement of therapy.In case of loss of response to rule out progressive disease or cytogenetic evolution*BM* Bone marrow, *FBC* full blood count, *T*~*4*~ thyroxine, *TSH* thyroid-stimulating hormone

Likewise, the safety, efficacy, and pharmacokinetics of lenalidomide therapy have not been fully investigated in patients with evidence of hepatic impairment, or those with frank hepatic dysfunction. Clinical trials conducted to date have excluded patients with inadequate hepatic function, with individual trials using different serum transaminase measures as exclusion criteria; most trials excluded patients with serum transaminase levels greater than three times the upper limit of normal.

Pharmacokinetic studies have revealed that the co-administration of lenalidomide with digoxin may increase the maximal digoxin concentration, although the area under the concentration--time curve remained unchanged \[[@CR10]\]. Importantly, lenalidomide does not interact with the cytochrome P450 system, and so, can be confidently co-administered with other medications metabolized by this route (Celgene data on file) \[[@CR10]\]. This latter finding is particularly relevant for older patients, who may be more likely to be receiving concomitant medications for co-morbidities. The expert panel concurred with the current prescribing information for lenalidomide and recommended that patients taking digoxin should have their digoxin plasma levels monitored periodically (Table [3](#Tab3){ref-type="table"}).

Treatment with lenalidomide in del(5q) MDS {#Sec3}
==========================================

The time-to-response during lenalidomide therapy was evaluated in the larger of the two pivotal clinical trials \[[@CR8]\]. For most patients, the median time to initiation of the transfusion-independent period was 4.6weeks, but responses have been noted to take up to 12months \[[@CR8]\]. Therefore, the expert panel recommends a treatment duration of at least 4months in order to obtain an initial response (Table [4](#Tab4){ref-type="table"}). Patients were followed for a median of 104weeks, but as more than half of them remained transfusion-free at this assessment point, the median duration of transfusion independence could not be calculated. Encouragingly, among the pooled patients with MDS with a del(5q) abnormality from the two studies \[[@CR8], [@CR9]\], transfusion independence and major erythroid response were maintained for a median duration of at least 2years \[[@CR12]\]. Even though there are anecdotal reports of long-lasting erythroid remissions in some patients with hematological complete response who discontinued lenalidomide, the panel recommends continuation of lenalidomide treatment in responders for as long as it is tolerated. In patients where the dose has initially been reduced for mild adverse events, dose escalations may be considered (Table [4](#Tab4){ref-type="table"}). In responders with high ferritin levels due to long transfusion histories who achieve normal hemoglobin levels, lenalidomide treatment should be continued and therapeutic phlebotomy be considered to reduce the secondary iron overload. In responders who discontinue due to adverse events, the panel recommends checking for response continuation before initiating another treatment (Table [4](#Tab4){ref-type="table"}). Preliminary data show that prolonged treatment with lenalidomide does not increase the risk of transition to acute myeloid leukemia \[[@CR13]\]. Of note, there are reports of patients acquiring additional cytogenetic abnormalities while on lenalidomide \[[@CR8]\], but at this time the relevance of this phenomenon is not entirely clear. Until there is data to the contrary, patients with continuous hematological response should remain on the drug. Patients losing their response and developing a complex karyotype should be approached as they would be in the absence of lenalidomide, and alternative therapies, including transplantation, should be considered. Table 4Recommendations for treatment duration Recommendation(s)Initial treatmentTreatment should be continued for at least 4 months in order to obtain an initial responsePatients who Have a complete hematological responseContinue lenalidomide therapy for as long as it continues to be well tolerated to avoid relapse (both erythroid and cytogenetic) Have a partial responseContinue lenalidomide therapy, and consider an escalation of the lenalidomide dose to a maximum of 10 mg per day, if tolerable Discontinue treatment because of adverse eventsPatients should not begin another therapy immediately; it is recommended to wait 8--12 weeks to determine whether the response continues

Tolerability of lenalidomide in del(5q) MDS {#Sec4}
===========================================

Lenalidomide has been shown to be well tolerated in the two clinical trials reported to date \[[@CR8], [@CR9]\]. The most commonly reported adverse events of grade 3 or 4 severity were neutropenia (55%), thrombocytopenia (44%), anemia (7%), leukopenia (6%), rash (6%), diarrhea (3%), pruritus (3%), pneumonia (3%), and fatigue (3%) \[[@CR8]\].

Management of hematological adverse events {#Sec5}
------------------------------------------

Hematological adverse events, including neutropenia and thrombocytopenia, were the most common adverse events with lenalidomide therapy and the most frequent reasons for dose adjustment \[[@CR9]\]. As such, thrombocytopenia and neutropenia should be expected to occur in most patients---in fact, they appear to be associated with a higher likelihood of a response to therapy \[[@CR14]\]. In general, regular monitoring of blood cell counts is recommended (Table [3](#Tab3){ref-type="table"}).

The majority of hematological adverse events (62%) occurred early in the course of treatment (within the first 8weeks) \[[@CR8]\]. Grade 3 or 4 neutropenia was reported in 55% of patients \[[@CR8]\]. Monitoring and, in some cases, additional treatment with granulocyte colony-stimulating factor (G-CSF) is recommended (Tables [3](#Tab3){ref-type="table"} and [5](#Tab5){ref-type="table"}, and Fig. [1](#Fig1){ref-type="fig"}). Neutropenic sepsis was the only reported cause of death (occurring in three patients) that was regarded as possibly related to the study drug \[[@CR8]\], therefore, patients should receive clear guidance on how to react in the event of febrile neutropenia (Table [5](#Tab5){ref-type="table"}). Grade 3 or 4 thrombocytopenia was observed in 44% of patients \[[@CR8]\]. In some thrombocytopenic patients, interruption of lenalidomide treatment may be necessary (Table [5](#Tab5){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). Lenalidomide has not been tested in patients with a baseline neutrophil count \<500 × 10^6^/l or baseline platelet count \<50 × 10^9^/l. Fig. 1Recommendations for the management of **a** neutropenia and **b** thrombocytopenia. ^a^No consensus was reached, recommendation is based on the opinion of some of the panel members *G-CSF* granulocyte colony-stimulating factorTable 5Recommendations for the management of hematological adverse events Recommendation(s)NeutropeniaFor treatment recommendations for neutropenia see Fig. [1](#Fig1){ref-type="fig"}Febrile neutropeniaProvide patients with clear guidance on how to react in the event of febrile neutropenia (patient education, specialized hematological care at all times, and broad-spectrum antibiotics within 3 h of fever onset)ThrombocytopeniaFor treatment recommendations for thrombocytopenia see Fig. [1](#Fig1){ref-type="fig"}VTEVTE prophylaxis is not generally recommended in patients with MDS. Combining lenalidomide with erythropoietin is also not recommended.If erythropoietin is used, be aware of a potentially increased risk of VTE. Patients should be informed about the risk of VTE and monitored for symptomsIf VTE does occur, interrupt lenalidomide treatment, treat the VTE, and carefully re-introduce lenalidomide once stable anticoagulation has been establishedPolycythemiaLenalidomide should be continued and phlebotomy considered, depending on ferritin levels. Although polycythemia is usually transient, treatment interruption may be necessary if additional risk factors for VTE are present*MDS* myelodysplastic syndromes, *VTE* venous thromboembolism

In the opinion of the panel, patients presenting with a neutrophil count \<1,000 × 10^6^/l prior to the start of lenalidomide therapy can still be treated with lenalidomide if G-CSF is co-administered. When neutropenia occurs during lenalidomide therapy, interruption of the lenalidomide treatment schedule might be necessary (Table [5](#Tab5){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). When thrombocytopenia (platelet count \<25 × 10^9^/l) is diagnosed at presentation, based on the rationale that once a response is achieved thrombocytopenia is likely to resolve, some experts would consider administering lenalidomide with platelet support (Table [5](#Tab5){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). However, other experts advise against the use of lenalidomide in patients with a platelet count \<50 × 10^9^/l because there is a risk of sustained deterioration of thrombocytopenia, despite an erythroid response. In some patients responding to lenalidomide, polycythemia may occur \[[@CR8]\]; if appropriate, therapeutic phlebotomy or interruption of lenalidomide therapy may be considered (Table [5](#Tab5){ref-type="table"}).

Grade 3 or 4 venous thromboembolism (VTE) was observed in 3% of patients \[[@CR8]\]. Generally, the risk of VTE is increased if there is a history of superficial vein thrombosis, or previous VTE \[[@CR15], [@CR16]\]. It is unknown if this applies to patients treated with lenalidomide as well. Nevertheless, these patients should be carefully monitored. In patients with a history of previous VTE, low-molecular-weight heparin should be used to prevent recurrent thrombosis. Although aspirin is effective in the prevention of thrombosis in multiple myeloma, aspirin cannot be recommended alongside lenalidomide as lenalidomide frequently leads to grade 3 or 4 thrombocytopenia in patients with MDS with del(5q). There are insufficient data on low-dose coumadin treatment for the prophylaxis of VTE, and therefore the panel did not recommend its use. Of particular relevance to patients with MDS, VTE risk is increased by concomitant erythropoietin use \[[@CR17]\]. Since the incidence of VTE in patients with lenalidomide-treated MDS is generally low \[[@CR8]\], prophylaxis in patients without antecedents of VTE is not recommended. If VTE does occur, it should be treated according to standard protocols. Treatment with lenalidomide should be interrupted until stable anticoagulation is achieved and then carefully reintroduced (Table [5](#Tab5){ref-type="table"}). Once VTE has occurred during lenalidomide therapy, patients must remain on anticoagulation therapy as lenalidomide treatment continues.

Management of non-hematological adverse events {#Sec6}
----------------------------------------------

Unlike thalidomide, lenalidomide does not lead to dose-dependent peripheral neuropathy or somnolence \[[@CR18]\], but other non-hematological adverse events (NHAEs) may occur. The most common NHAEs (all grades) associated with lenalidomide therapy are diarrhea (49%), pruritus (42%), rash (36%), and fatigue (31%) \[[@CR10]\]. The most commonly reported grade ≥3 NHAEs were rash (6%), fatigue (3%), diarrhea (3%), and pruritus (3%) \[[@CR8]\]. In general, should NHAEs arise during lenalidomide therapy, alternative causes should be ruled out and symptomatic treatment initiated (Table [6](#Tab6){ref-type="table"}). Dry skin and pruritus occur regularly, and itching of the scalp is a characteristic adverse event during the first few weeks of therapy. These NHAEs are usually self-limiting and seldom need treatment. Unselective antihistamines (e.g., clemastine) are usually helpful. In severe cases, a short course of systemic corticosteroids (10mg of prednisone or equivalent), or local steroid application may be helpful. Rash often resolves spontaneously with time \[[@CR19]\], and the panel do not recommend discontinuation of lenalidomide treatment should rash arise; however, in patients with severe or persistent rash, the temporary interruption of lenalidomide may be necessary (Table [6](#Tab6){ref-type="table"}). Table 6Recommendations for management of non-hematological adverse events (NHAEs)NHAERecommendation(s)RashUsually resolves within 2--3 weeks, no interruption of lenalidomide treatment neededIf required treat with unselective antihistamines (e.g. clemastine), topical steroids, or a short course (14 days) of oral 10 mg prednisoneIf rash is severe or persists after treatment, lenalidomide should be interrupted until rash resolves. In the experience of the panel, lenalidomide can be restarted thereafter without recurrence of rashDiarrheaTreat symptomatically after ruling out other underlying causesHypothyroidismIn case of hypothyroidism, thyroid replacement therapy must be initiatedOther NHAEsTreat symptomatically after ruling out other underlying causes such as anemia or autoimmune disorders

Diarrhea is a frequent problem and may impact on a patient's quality of life. Patients with known lactose intolerance should add lactase to their diet, as lenalidomide capsules contain small amounts of lactose. Diverse symptomatic therapies have been reported to be effective in those patients, including, but not limited to, loperamide, pipaverium bromide, uzara root extract, and tinctura opii. Muscle cramps have been reported by a number of patients after a variable time of lenalidomide intake. Magnesium dietary supplements may be tried, but are usually of limited value. Quinine sulphate (up to 200mg thrice-daily) works well, however, physicians should check for other cytochrome-P450-interacting drugs (e.g., sotalol, terfenadine, astemizole, voriconazole, erythromycin, rifampicin, and cisapride) that might prolong QT time in these patients. Patients who experience fatigue will be likely to benefit from counselling \[[@CR20]\], and in cases of severe fatigue, dose reduction may be needed. Hypothyroidism has been reported in approximately 7% of patients \[[@CR10]\]. It is almost exclusively of autoimmune cause. Patients should be screened for hypothyroidism every other month during the course of treatment (Table [3](#Tab3){ref-type="table"}). If hypothyroidism is confirmed, hormone replacement therapy is indicated (Table [6](#Tab6){ref-type="table"}). Patients losing their response to lenalidomide during treatment may have developed either hypothyroidism or hypogonadism, and should be screened for both conditions.

Conclusions {#Sec7}
===========

The approval of lenalidomide for the treatment of MDS patients with low-risk or intermediate-1-risk disease with a deletion of chromosome 5q represents a significant step forward for this underserved group of patients. The key goal of the strategies presented here is to avoid unnecessary dose delays and reductions, and to maximize probability of response. Patient selection is straightforward, as efficacy does not appear to be influenced appreciably by relevant prognostic factors including age, prior erythropoietin therapy, sex, French--American--British type, or IPSS score. Treatment should be continued for a minimum of 4months to ensure treatment response. Neutropenia and thrombocytopenia are the most common adverse events during lenalidomide therapy but can be managed by the introduction of G-CSF and dose interruption. Other side-effects are generally manageable, and a range of simple (prophylactic) interventions are recommended to address the more common and more serious associated adverse events.
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